IRS1
IRS1 is an integrin-targeted, ROS-responsive self-assembling peptide prodrug molecule with selective anti-cancer activity against integrin-overexpressing tumor cells. IRS1 contains an RGD motif for integrin binding, can covalently bind to DR4/DR5, and promotes DR4/DR5 aggregation. After oxidation by ROS, IRS1 undergoes a morphological transition from nanoparticles to nanofibers, exposes the pharmacophore of Chlorambucil (HY-13593), disrupts cell membrane integrity, activates the extrinsic apoptosis pathway, and can penetrate and inhibit the three-dimensional uveal melanoma spheroid model. IRS1 can be used for the research of uveal melanoma.
For research use only. We do not sell to patients.
- Formula: C84H105Cl2F3N13O15PS
- Molecular Weight:1727.75
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
All Caspase Isoforms
More
Biological Activity
Description
IC50 & Target
[1]|
Caspase-3 |
Caspase-8 |
In Vitro
IRS1 undergoes complete ROS-induced oxidation within 420 min in PBS solution, accompanied by a structural transition from nanoparticles to nanofibers, enabling covalent binding with cysteine; it forms micelles in aqueous solution with a critical micelle concentration of 29.0 μM[1].
IRS1 (0-400 μM; 72 h) selectively inhibits integrin-overexpressing tumor cells (MuM-2B, HeLa, MDA-MB-231), exhibits extremely low toxicity to normal cells (ARPE-19, 293T), and shows weak activity against integrin-low-expressing OCM-1A cells[1].
IRS1 (25-200 μM; 24 h) preferentially accumulates at the plasma membrane of MuM-2B cells, forming a dense fibrous network and impairing membrane integrity[1].
IRS1 (0-100 μM; 24 h) impairs the migration and invasion abilities of MuM-2B cells in a dose-dependent manner, with the inhibitory effect reaching its peak at the concentration of 100 μM[1].
IRS1 (0-400 μM; 0-72 h) effectively penetrates MuM-2B 3D spheroids and inhibits their growth in a dose-dependent manner, while it exerts minimal effects on integrin-low-expressing ARPE-19 spheroids after 72 h of incubation[1].
IRS1 (0-200 μM; 24 h) induces apoptosis in MuM-2B cells via activating the extrinsic caspase-8-mediated pathway, and upregulates the expression of DR4 and DR5 in MuM-2B cells[1].
IRS1 (200 μM; 24 h) triggers a robust transcriptomic response in MuM-2B cells, activates death receptor and apoptosis pathways, and simultaneously inhibits metabolic and DNA replication pathways[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
-
Cell Line:MuM-2B, HeLa, MDA-MB-231, OCM-1A, ARPE-19, 293T
-
Concentration:0, 25, 50, 100, 200, 400 μM
-
Incubation Time:72 h
-
Result:Inhibited >70% of MuM-2B cell growth at 400 μM.
Inhibited ~60% of HeLa cell growth at 400 μM.
Inhibited ~40% of MDA-MB-231 cell growth at 400 μM.
Inhibited ~20% of OCM-1A cell growth at 400 μM.
Inhibited ~10% of ARPE-19 cell growth at 400 μM.
Inhibited ~15% of 293T cell growth at 400 μM.
-
Cell Line:MuM-2B
-
Concentration:200 μM
-
Incubation Time:24 h
-
Result:Increased apoptotic cells from 6.0% to 61.4% at 200 μM.
-
Cell Line:MuM-2B
-
Concentration:0, 12.5, 25, 50, 100, 200 μM
-
Incubation Time:24 h
-
Result:Decreased caspase-3, caspase-8 expression at 200 μM.
Increased cleaved PARP, cleaved caspase-8 at 200 μM.
-
Cell Line:MuM-2B
-
Concentration:0, 25, 50, 100 μM
-
Incubation Time:24 h
-
Result:Impaired MuM-2B cell migration and invasion.
In Vivo
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:BALB/c nude (female, 7-8 weeks old)[1]
-
Dosage:5 mg/kg; 10 mg/kg
-
Administration:i.v.; every 3 days; 5 doses
-
Result:Increased tumor volume to ~4.1-fold initial size at 15 days in the 5 mg/kg group.
Maintained nearly unchanged tumor volume at 15 days in the 10 mg/kg group.
Reduced average tumor weight to 0.25 g in the 5 mg/kg group and 0.07 g in the 10 mg/kg group, compared to 0.41 g in the saline control group.
Induced 21-fold higher fluorescence intensity via TUNEL staining in the 10 mg/kg group than the saline group.
Caused no significant body weight changes in either treated group.
Showed no pathological abnormalities in major organs (heart, liver, spleen, lung, kidney) via H&E staining in either treated group.
Resulted in serum hepatic and renal function markers (ALT, AST, BUN, CREA) comparable to the saline control group in either treated group.
Chemical Information
-
Molecular Weight 1727.75
-
Formula C84H105Cl2F3N13O15PS
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocols
-
Apoptosis
Apoptosis, also called programmed cell death, is generally characterized by distinct morphological characteristics.
-
TUNEL staining for apoptotic DNA fragmentation
TUNEL staining detects DNA strand breaks by using terminal deoxynucleotidyl transferase to add labeled nucleotides to exposed 3′-OH DNA termini, generating either microscopic staining in fixed cells or tissue sections, or fluorescence/cytometric signal in cell suspensions. TUNEL positivity reflects DNA fragmentation but should not be interpreted alone as definitive apoptosis, because TUNEL can also label necrotic, autolytic, mechanically damaged, or DNA-repair-associated DNA breaks.
-
Annexin V plus membrane-impermeant dye apoptosis staining
Annexin V-based apoptosis assays rely on the detection of phosphatidylserine (PS) externalization from the inner leaflet of the plasma membrane to the outer leaflet, an early biochemical hallmark of apoptosis. Fluorescently labeled Annexin V binds PS in a calcium-dependent manner, enabling identification of early apoptotic cells by flow cytometry or fluorescence microscopy. When combined with a membrane-impermeant DNA-binding dye (e. g. , propidium iodide), this approach allows discrimination between viable (Annexin V−/dye−), early apoptotic (Annexin V+/dye−), and late apoptotic or necrotic (Annexin V+/dye+) cell populations by assessing membrane integrity and PS exposure.
-
ROS/oxidative-stress fluorescent staining
ROS/oxidative-stress fluorescent staining uses cell-permeant fluorogenic probes that become fluorescent after oxidation inside cells or tissues; commonly used examples include DCFH-DA/DCFDA for broad cellular oxidant detection, DHE for superoxide-related signal detection, MitoSOX for mitochondrial superoxide-related signal detection, and CellROX probes for oxidative-stress-associated fluorescence readouts. The assay detects probe oxidation rather than a single ROS species unless the probe and analysis method have been chemically validated for that species. DCFH-DA enters cells, is deacetylated by intracellular esterases to DCFH, and produces fluorescent DCF after oxidation, so the readout is used as an operational measure of total cellular oxidative stress rather than a species-specific ROS measurement. DHE and MitoSOX can report superoxide-related oxidation, but red fluorescence alone can include non-specific ethidium-like oxidation products; HPLC or optimized spectral approaches are
-
Apoptosis Solutions
Apoptosis is a regulated, generally non-lytic cell-death pathway that removes unwanted, damaged, infected, or abnormal cells through coordinated morphological changes, caspase activation, DNA fragmentation, and membrane remodeling. The intrinsic apoptosis pathway is controlled mainly by mitochondrial outer membrane permeabilization, BCL-2 family proteins, cytochrome c release, apoptosome formation, caspase-9 activation, and downstream executioner caspase-3/7 activation. The extrinsic apoptosis pathway is initiated by death receptors such as Fas, TNFR, and TRAIL receptors, which recruit adaptor proteins and activate caspase-8 before engaging executioner caspases or mitochondrial amplification through BID cleavage. Apoptosis is linked to many phenotypes, including cancer cell killing, tissue homeostasis, immune regulation, neurodegeneration, infection response, and treatment-induced cytotoxicity; unresolved questions include how apoptosis interacts with necroptosis, pyroptosis, ferroptos
Purity & Documentation
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)